Femasys (NASDAQ:FEMY) Issues Quarterly Earnings Results

Femasys (NASDAQ:FEMY) issued its quarterly earnings results on Tuesday. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.07, FiscalAI reports. Femasys had a negative return on equity of 764.26% and a negative net margin of 960.80%.The business had revenue of $0.81 million during the quarter, compared to the consensus estimate of $1.06 million.

Femasys Price Performance

Shares of NASDAQ:FEMY opened at $0.42 on Thursday. Femasys has a twelve month low of $0.31 and a twelve month high of $1.30. The company has a current ratio of 1.16, a quick ratio of 0.61 and a debt-to-equity ratio of 0.01. The company has a market cap of $25.30 million, a PE ratio of -0.84 and a beta of -2.28. The company’s 50 day moving average is $0.54 and its 200 day moving average is $0.63.

Institutional Trading of Femasys

A number of hedge funds and other institutional investors have recently made changes to their positions in FEMY. Geode Capital Management LLC raised its holdings in shares of Femasys by 50.8% during the fourth quarter. Geode Capital Management LLC now owns 389,280 shares of the company’s stock worth $224,000 after purchasing an additional 131,052 shares during the last quarter. Banco BTG Pactual S.A. purchased a new stake in Femasys in the fourth quarter valued at $88,000. Jane Street Group LLC acquired a new stake in Femasys during the 4th quarter worth about $62,000. State Street Corp grew its position in Femasys by 43.5% during the 4th quarter. State Street Corp now owns 80,869 shares of the company’s stock worth $47,000 after purchasing an additional 24,500 shares during the period. Finally, Cetera Investment Advisers purchased a new position in shares of Femasys during the 4th quarter valued at about $36,000. Institutional investors and hedge funds own 65.27% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on FEMY. Lake Street Capital initiated coverage on shares of Femasys in a research note on Tuesday, March 3rd. They set a “buy” rating and a $1.50 price target on the stock. Wall Street Zen lowered Femasys from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Femasys in a research report on Thursday, January 22nd. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Femasys has an average rating of “Moderate Buy” and a consensus price target of $5.50.

About Femasys

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.